{"filings":[{"id":2106004,"accession_number":"0001193125-26-338009","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-08-06T20:10:58+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q2 2026 revenue $1.4M, cash $330.3M; Varseta-M registrational study planned for 1H 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.4M vs $18.7M YoY, driven by completion of BMS collaboration and lower Astellas activity.","Cash, equivalents and investments $330.3M; plus $37M July Regeneron payment; runway to 2H 2028.","Varseta-M Phase 1 data update expected end-2026; registrational study in CRC planned for 1H 2027.","Regeneron collaboration expanded; $37M target selection payment received; potential milestones up to ~$4B.","Board and leadership strengthened: Dr. Charles Fuchs, Mamata Gokhale, Alejandra Carvajal appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":11677000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1868480,"accession_number":"0001193125-26-316929","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-07-27T12:05:07+00:00","items":["5.02"],"status":"ready","headline":"CytomX appoints Charles Fuchs to Board of Directors as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Fuchs appointed effective July 24, 2026, as Class II director with term expiring at 2029 annual meeting.","Receives option to purchase 118,000 shares at closing price on appointment date, vesting monthly over 3 years.","Will receive standard non-employee director compensation and enter into indemnification agreement.","No material transactions or arrangements between Dr. Fuchs and the Company exceeding $120,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1196636,"accession_number":"0001193125-26-277631","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-06-22T20:52:39+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CytomX shareholders approve charter amendment to double authorized common stock and equity plan increases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter Amendment increased authorized common stock from 300M to 600M shares, effective June 22, 2026.","2015 Plan Amendment adds 6.5M shares to equity incentive plan; ESPP Amendment adds 1M shares.","Directors Matthew P. Young and Elaine V. Jones re-elected to Class II until 2029 Annual Meeting.","Advisory vote on executive compensation passed (147.1M for, 1.7M against); company will hold Say-on-Pay annually.","Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 183M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":833959,"accession_number":"0001193125-26-255467","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-06-03T20:15:15+00:00","items":["1.01"],"status":"ready","headline":"CytomX and Regeneron expand collaboration; CytomX to receive $37M in target nomination payments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 4 adds up to eight new collaboration programs; Regeneron nominates first two.","CytomX receives $37M aggregate target nomination payments for the two nominated programs.","Total potential milestones under expanded agreement are up to approximately $4 billion.","Royalty rates on global net sales unchanged; program selection period extended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93240,"accession_number":"0001193125-26-211920","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q1 rev $10.3M; cash $346.7M; Varseta-M dose optimization enrollment complete (40 pts)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $10.3M vs $50.9M YoY; decrease driven by completion of BMS and Amgen collaborations.","Cash $346.7M (Dec 31: $137.1M) includes $234.2M net from March equity offering; runway to at least 2H 2028.","Varseta-M dose optimization enrollment completed (40 patients); data update in 2H 2026 to inform monotherapy dose and potential registrational trial in late-line CRC.","Varseta-M + bevacizumab Phase 1 combo underway; initial data by 1H 2027; Phase 1/2 chemo combo starts 2H 2026.","CX-801 (PROBODY IFNα2b) Phase 1 combo with Keytruda enrolling third dose level; initial combo data expected end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":10258000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104685,"accession_number":"0001193125-26-115958","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytomX closes public offering of ~47M shares/warrants, net proceeds ~$234.4M for pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 45,990,567 shares at $5.30 and pre-funded warrants for 1,179,245 shares at $5.29999 each.","Underwriters granted 30-day option to purchase up to 7,075,471 additional shares at the offering price.","Net proceeds estimated at approximately $234.4 million after underwriting discounts and expenses.","Proceeds to fund continued development of Varseta-M and other pipeline programs, plus general corporate purposes.","Offering closed on March 19, 2026 under an underwriting agreement dated March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104684,"accession_number":"0001193125-26-107152","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX reports 2025 revenue $76.2M, down 45% YoY; cash $137.1M; Astellas collaboration ends","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $76.2M (down from $138.1M in 2024) on completion of BMS collaboration and lower collaboration milestones.","Cash and investments $137.1M at Dec 31, 2025, up from $100.6M; cash runway to Q2 2027.","Astellas terminated preclinical alliance effective Q2 2026; research with BMS, Amgen, Regeneron, Moderna continues.","Varseta-M Phase 1 data positive; FDA alignment for potential registrational trial in late-line CRC targeted mid-2026.","CX-801 Phase 1 combo with KEYTRUDA in melanoma initial proof-of-concept data expected by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120985,"accession_number":"0001193125-25-269533","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q3 2025 revenue $6.0M (down 82% YoY); cash $143.6M; pipeline on track for key milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.0M in Q3 2025 vs $33.4M in Q3 2024; cash, equivalents and investments $143.6M, runway to Q2 2027.","R&D expenses $15.3M (-$6.1M YoY); G&A $6.4M (-$1.5M YoY); total operating expense $21.7M.","CX-2051 Phase 1 enrollment ~100 patients by Q1 2026 data update; Phase 1b combo with bevacizumab starts Q1 2026.","CX-801 Phase 1 monotherapy biomarker data at SITC 2025; combo with KEYTRUDA dose escalation enrolling 2nd dose level.","Appointed Rachael Lester as SVP, Chief Business Officer in October 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":75538000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137586,"accession_number":"0001193125-25-179463","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytomX reports Grade 5 adverse event in CX-2051 Phase 1 trial; FDA notified, study continues","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single Grade 5 acute kidney injury occurred in patient with solitary kidney; event believed secondary to nausea, vomiting, diarrhea.","Safety Review Committee convened July 14, 2025, supported continued study execution and enrollment.","FDA notified on July 18, 2025; company aware on July 11, 2025.","CX-2051 dose expansions at 7.2, 8.6, and 10 mg/kg each enrolled ~20 patients as planned.","Phase 1 data update expected by Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137585,"accession_number":"0000950170-25-105053","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q2 2025 cash $158.1M; positive CX-2051 Phase 1 data; $100M offering closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.7M in Q2 2025 vs $25.1M in Q2 2024; operating expenses fell to $19.9M from $33.6M.","Cash, equivalents and investments $158.1M at June 30, 2025, up from $79.9M on March 31, 2025; cash runway to Q2 2027.","Positive interim data from CX-2051 Phase 1 in advanced colorectal cancer; dose expansions initiated at 7.2, 8.6, 10 mg/kg Q3W.","CX-2051 Phase 1 data update on ~70 patients by Q1 2026; Phase 2 study in late-line CRC expected in 1H 2026.","Completed $100M underwritten offering, net proceeds $93.4M; CX-801 plus KEYTRUDA dose escalation started for advanced melanoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":69575000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154954,"accession_number":"0001193125-25-140739","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CytomX stockholders approve amended equity plan adding 4.38M shares; three directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected three Class I directors: Sean McCarthy (16.4M for), Mani Mohindru (19.7M for), Zhen Su (19.7M for), terms until 2028.","Amended 2015 Equity Plan approved; shares available increase to 6,300,000 from prior pool plus 4,381,320 new shares.","Employee Stock Purchase Plan amended to remove evergreen automatic increase and remove 10-year expiration, now indefinite.","Ratified Ernst & Young as auditor for FY2025; advisory vote on exec compensation approved with ~22.9M for, 5.3M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154953,"accession_number":"0001193125-25-129470","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytomX regains Nasdaq minimum bid price compliance as of May 23, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff notified company on May 27, 2025, of compliance regained.","Closing price ≥ $1.00 for 10 consecutive trading days ended May 23, 2025.","Resolves previous deficiency notice from February 24, 2025.","Matter is now closed with no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154952,"accession_number":"0001193125-25-118805","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytomX nets $93.4M in underwritten common stock offering; 76.9M shares at $1.30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 76,923,076 shares of common stock at $1.30/share, generating ~$93.4M in net proceeds after underwriting discounts and expenses.","Proceeds to be used for research and development, general corporate purposes, and working capital.","Underwriting syndicate led by Jefferies and Piper Sandler & Co.","Offering closed on May 13, 2025; shares issued under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154951,"accession_number":"0001193125-25-117245","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CytomX Q1 revenue $50.9M; CX-2051 Phase 1 shows 28% ORR in advanced CRC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $50.9M (up from $41.5M); operating expense $28.3M; cash $79.9M.","CX-2051 Phase 1: 28% ORR (5/18 confirmed PRs), 94% DCR, median PFS 5.8 months in advanced CRC.","Dose expansions started at 7.2, 8.6, 10 mg/kg Q3W; Phase 2 planned 1H 2026.","Astellas milestone $5M; cash runway into Q2 2026.","CX-801 Phase 1a data in melanoma expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":50917000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173464,"accession_number":"0000950170-25-034585","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Therapeutics 2024 revenue $138.1M (up 36% YoY); CX-2051 data expected 1H 2025; headcount cut 40%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $138.1M for FY2024 vs $101.2M in FY2023 (+36%); cash and investments $100.6M vs $174.5M at year-end.","Lead program CX-2051 (EpCAM ADC) Phase 1a initial data in advanced CRC expected 1H 2025; dose escalation at 7th dose level.","CX-801 (IFN-alpha) Phase 1a translational data in melanoma expected 2H 2025; monotherapy dose exceeds approved peginterferon dose.","CX-904 (EGFR-CD3 TCE) development discontinued by mutual decision with Amgen.","January 2025 restructuring reduced headcount ~40% to extend cash runway into Q2 2026; Astellas milestone triggered $5M payment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173463,"accession_number":"0001193125-25-036794","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CytomX receives Nasdaq delisting notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified CytomX on Feb 24, 2025 that common stock bid price stayed below $1.00 for 30 consecutive business days through Feb 21, 2025.","Company has 180 calendar days, until August 25, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.","If not cured by the deadline, CytomX may transfer to Nasdaq Capital Market for an additional 180-day compliance period.","Company will monitor bid price and consider options, but there is no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173462,"accession_number":"0001193125-25-019257","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX CBO Jeffrey Landau to depart effective Feb 7, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Landau, SVP, Chief Business Officer, and Head of Strategy, will leave the company on February 7, 2025.","Separation agreement provides economic payments consistent with existing severance and change of control agreement.","Separation includes a general release of claims against the company.","No replacement for Landau's role has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173461,"accession_number":"0001193125-25-002165","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"CytomX to cut ~40% of workforce, focus on CX-2051, extend cash runway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~40%, primarily affecting G&A and non-partnered research staff, substantially complete in Q1 2025.","Estimated restructuring charges of $5M to $6M, mostly severance, recorded in Q1 2025.","Cash payments of ~$5M starting Q1 2025; cash runway extended into Q2 2026.","Company to prioritize CX-2051 (EpCAM PROBODY ADC) and support research collaborations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190452,"accession_number":"0000950170-24-123314","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q3 revenue $33.4M (up 26% YoY); cash $117.6M; pipeline programs advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $33.4M in Q3 2024, up from $26.4M in Q3 2023 (+26.5%).","Cash & investments $117.6M as of Sep 30, 2024 (down from $137.2M at June 30); runway to end of 2025.","CX-904 Phase 1a cleared 15 mg dose; Phase 1b possible in 2025 pending dose/schedule optimization.","CX-2051 Phase 1a in colorectal cancer in fifth dose cohort; initial data expected H1 2025.","CX-801 Phase 1a started, first patient dosed; initial data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":100010000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206952,"accession_number":"0000950170-24-093936","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q2 2024 cash $137.2M; revenue $25.1M; CX-904 update expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $137.2M at June 30, 2024, down from $150.3M at March 31, 2024.","Total revenue $25.1M in Q2 2024, up from $24.7M in Q2 2023; R&D expense $25.2M incl. $5M milestone to AbbVie.","CX-904 (EGFRxCD3) Phase 1a enrollment continues in PDAC, NSCLC, HNSCC; program update expected by end of 2024.","CX-2051 (EpCAM ADC) Phase 1 dose escalation in third cohort; initial data expected in first half of 2025.","CX-801 (IFNα2b cytokine) first clinical site active; initial data expected in 2025; $10M Astellas milestones achieved YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":66578000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224240,"accession_number":"0001193125-24-162652","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX Therapeutics appoints Chris Ogden as CFO effective June 15, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Ogden promoted from SVP Finance & Accounting to CFO, effective June 15, 2024.","Ogden continues as Principal Accounting and Financial Officer, roles held since September 2022.","Granted option to purchase 75,000 shares and RSU award for 17,500 shares under 2015 Equity Incentive Plan.","No family relationships or arrangements with other parties in connection with his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224239,"accession_number":"0001193125-24-141699","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Stockholders approve doubling authorized common stock to 300M shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Charter amendment to increase authorized common stock from 150M to 300M shares approved with 42.7M for, 3.2M against.","Class III directors Ashworth, Meyers, and Gilbert each elected with >24M votes for; broker non-votes of 17.6M.","Ratification of Ernst & Young as auditor for FY2024 passed with 46.5M votes for.","Advisory vote on executive compensation approved with 27.4M for, 1.9M against, 17.6M broker non-votes.","All four stockholder proposals at May 15 Annual Meeting were approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224238,"accession_number":"0001193125-24-134284","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CytomX reports positive Phase 1a data for CX-904: no CRS, 33% response rate in pancreatic cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CX-904 demonstrated favorable safety: no CRS of any grade in step-dosing; no Grade >1 CRS overall.","In 6 efficacy-evaluable pancreatic cancer patients, 2 confirmed partial responses (33%) and all 6 had disease control.","One patient achieved 83% tumor reduction at 6 mg; another 51% at 5 mg; both remained on treatment.","Preliminary PK/PD data support PROBODY T-cell engager mechanism: maintained masking and CD8+ T-cell margination.","Dose escalation continues; Phase 1b expansion in EGFR-positive tumors planned with partner Amgen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224237,"accession_number":"0000950170-24-055598","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q1 revenue $41.5M, up 77% YoY; positive early CX-904 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $41.5M vs $23.5M YoY; cash $150.3M at Mar 31, 2024.","CX-904 (EGFRxCD3) shows favorable safety; 2 of 6 pancreatic patients with confirmed partial responses.","CX-2051 (EpCAM ADC) first patient dosed Apr 2024; first dose cohort cleared; initial data H1 2025.","CX-801 (IFNα2b) to start Phase 1 in Q2 2024; collaboration with Merck for KEYTRUDA combo.","Achieved $10M in Astellas milestones for two T-cell engager programs; Dr. Zhen Su appointed to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":41463000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243583,"accession_number":"0001193125-24-075211","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"CytomX appoints Zhen Su to Board; adopts amended bylaws for stockholder proposals","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zhen Su, M.D., M.B.A., appointed to Board as Class I director effective March 20, 2024, filling a vacancy.","Dr. Su receives standard non-employee director compensation and an option to purchase 76,000 shares vesting over three years.","Board adopted Amended and Restated Bylaws to modernize stockholder nomination and proposal procedures, including removal of 'acting in concert' provisions.","Bylaw amendments effective immediately with clarifying and technical changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243582,"accession_number":"0000950170-24-029207","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX FY2023 revenue $101.2M, operating expenses down 30%; BMS discontinues 986288, CX-904 data H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $101.2M (up from $53.2M in 2022); operating expenses $107.7M (down from $154.5M).","Cash $174.5M at Dec 31, 2023 vs $193.7M a year earlier; includes $30M from July 2023 BVF financing.","BMS notified CytomX it will not continue BMS-986288 beyond current Phase 2; research collaboration with multiple TCE programs continues.","CX-904 EGFRxCD3 Phase 1a data expected H2 2024; CX-2051 and CX-801 Phase 1 starts H1 2024 after IND clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260997,"accession_number":"0000950170-23-060221","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q3 revenue $26.4M, cash $194.1M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $26.4M vs $11.1M YoY; cash $194.1M (includes ~$30M from BVF financing, $16.8M Q3 burn).","R&D expense $16.4M (-46% YoY); G&A $6.8M (-35% YoY); no net income or EPS disclosed.","CX-904 Phase 1a dose escalation data expected H1 2024; backfilling cohorts initiated Q4 2023.","CX-2051 IND filing by end of 2023; Phase 1 in solid tumors in 2024 with mCRC priority.","BMS-986288 Phase 2 ongoing; proof-of-concept data in MSS CRC and NSCLC expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":74607000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278260,"accession_number":"0001193125-23-220087","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"CytomX Therapeutics regains exclusive worldwide rights to ADC CX-2029 from AbbVie","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained full worldwide rights to develop CX-2029, a CD71-targeting conditionally activated antibody drug conjugate.","AbbVie eligible for tiered sales royalties on CX-2029 ranging from low-to-mid single digit percentages.","CytomX to pay Seagen potential future milestones and tiered sales royalties (mid-to-high single digits) for linker payload tech.","Transition Agreement supersedes the terminated 2016 CD71 Co-Development and License Agreement with AbbVie."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278259,"accession_number":"0000950170-23-039793","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q2 revenue $24.7M (up 91% YoY); cash runway into H2 2025 after $30M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & investments $180.9M at June 30, 2023; $30M gross financing from BVF closed July 2023.","Revenue $24.7M (vs $12.9M Q2 2022) driven by BMS collaboration; R&D expenses fell to $20.7M.","CX-904 (EGFRxCD3) Phase 1 dose escalation data anticipated first half of 2024; backfill cohorts by end 2023.","IND filings for wholly-owned CX-2051 (EpCAM ADC) and CX-801 (IFNa2b) expected Q4 2023.","Appointed Dr. Wayne Chu as CMO; promoted Dawn Benson to SVP Quality and Product Manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":48223000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278258,"accession_number":"0001193125-23-180722","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CytomX raises $30M via private placement of units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $30M from unit sale at $2.08 each; closing expected July 3, 2023.","Each unit: 1 share or Pre-Funded Warrant ($0.00001 exercise, 20-yr term) plus Tranche 1 ($4.16, exp. 2025) and Tranche 2 ($6.24, exp. 2026) warrants.","No underwriter; resale registration statement to be filed within 60 days after closing.","Pre-funded and Tranche warrants may not be exercised if holder would exceed 9.99% ownership (adjustable to 19.99%).","Exercise price of Tranche warrants subject to reset if future offering below $4.16, but not below $2.08."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296373,"accession_number":"0001193125-23-170124","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CytomX Therapeutics stockholders elect directors, ratify auditor, approve say-on-pay at 2023 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Matthew P. Young re-elected to board with 23.8M votes for (0.7M against); Elaine V. Jones re-elected with 18.4M for (6.1M against).","Ratification of Ernst & Young as independent auditor for FY2023 passed with 43.3M for, 0.6M against.","Non-binding advisory vote on executive compensation approved with 22.1M for, 1.5M against, 0.9M abstain, and 19.3M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296372,"accession_number":"0000950170-23-019674","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q1 revenue $23.5M vs $9.0M YoY; cash $204.5M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $23.5M in Q1 2023, up from $9.0M Q1 2022, driven by BMS project progress, Astellas milestone, and AbbVie termination revenue recognition.","Cash, equivalents and investments $204.5M at Mar 31, 2023, versus $193.7M at Dec 31, 2022; includes $35M Moderna upfront and $5M Astellas milestone.","AbbVie terminated CD71 collaboration; CX-2029 not advanced to additional studies; CytomX evaluating full rights acquisition and next-gen CD71 strategies.","BMS advanced BMS-986288 (anti-CTLA-4 Probody) from Phase 1 to Phase 2 as lead next-gen CTLA-4 program.","Marcia Belvin promoted to Chief Scientific Officer; IND filings for CX-2051 and CX-801 targeted for H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":23499000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316851,"accession_number":"0000950170-23-009999","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX FY2022 revenue $53.2M; cash $194M; AbbVie terminates CX-2029; new Moderna/Regeneron deals","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 revenue $53.2M (+43% YoY); cash $194M vs $305M at Dec 2021.","Restructuring substantially complete; $7.7M in charges incurred in 2022.","AbbVie terminates CX-2029 collaboration; CytomX regains full rights to CD71 program.","CX-904 Phase 1 dose escalation progressing; IND filings for CX-801 & CX-2051 expected 2H 2023.","New collaborations: Moderna ($35M upfront) and Regeneron ($30M upfront) with up to $1.2B and $2B milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316850,"accession_number":"0001193125-23-067531","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CytomX says SVB exposure immaterial; cash near FDIC limit, $917K letter of credit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Operating cash at SVB at or near FDIC-insured limit of $250,000.","Standby letter of credit under office lease: ~$917,000 deposited at SVB.","Third-party investments held at outside custodians, not directly exposed to SVB.","Company does not consider SVB liquidity concern material to its operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316849,"accession_number":"0001193125-23-047460","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"CytomX restates 2018-2021 annual and 2018-2022 quarterly financials due to revenue recognition error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement affects timing of revenue from collaborations with Bristol-Myers Squibb, Astellas, AbbVie, and Amgen.","No impact on total revenue, cash position, or cash flows; only timing of revenue recognition changes.","Material weakness identified in internal control over financial reporting related to ASC 606 application.","Company plans to amend 2021 Form 10-K and restate 2021 and 2022 quarters in 2022 Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316848,"accession_number":"0001193125-23-002398","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"CytomX inks $35M upfront deal with Moderna for mRNA-Probody therapies; milestones up to $1.2B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $35M includes $5M pre-paid research funding; potential milestones total $1.2B.","Tiered royalties on net sales from high single digit to low-teen percentages per licensed product.","Moderna gets exclusive worldwide license to CytomX Probody platform for mRNA-encoded conditionally-activated therapies.","Moderna has a one-time option to participate in a future CytomX equity financing.","Collaboration covers oncology and non-oncology programs; Moderna can terminate on product-by-product basis after 2 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335099,"accession_number":"0001193125-22-290176","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"CytomX and Regeneron enter $30M upfront cancer bi-specific collaboration; up to $2B milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["CytomX receives $30M upfront from Regeneron; eligible for up to $2B in development/regulatory milestones.","Tiered royalties from high single digit to low-teen percentages on global net sales of licensed products.","Collaboration uses CytomX's Probody platform and Regeneron's Veloci-Bi bispecific platform for conditionally-activated cancer therapies.","Regeneron fully funds all preclinical, development, manufacturing, and commercialization activities worldwide.","CytomX grants exclusive worldwide royalty-bearing license to Regeneron for oncology; Regeneron may terminate programs on 30 days' notice after 2 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335098,"accession_number":"0000950170-22-023210","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q3 cash falls to $194.3M; revenue $16.9M; restructuring $7.1M; IND targets set for 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $194.3M as of Sep 30, 2022, down from $305.2M at Dec 31, 2021.","Revenue $16.9M for Q3 2022 vs $17.6M for Q3 2021, down ~4%.","R&D expense $30.4M, G&A $10.5M; restructuring charges $7.1M in Q3.","IND for CX-2051 and CX-801 expected H2 2023; CX-2029 sqNSCLC data update Q4 2022.","Company restructuring announced July 2022 to be completed by end of 2022; total ~$7.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":52217000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352541,"accession_number":"0001193125-22-250137","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-09-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX Therapeutics CFO Carlos Campoy to depart Sept 30; Chris Ogden named principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carlos Campoy, SVP and CFO, expected to terminate employment effective Sept 30, 2022.","Chris Ogden, SVP Finance and Accounting, assumes principal financial and principal accounting officer roles effective immediately.","Ogden's biographical details incorporated by reference from April 2022 proxy statement.","No family relationships or related party transactions between Ogden and the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352540,"accession_number":"0001193125-22-243709","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX enters consulting agreements with former COO and CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amy Peterson, former President and COO, to provide consulting at $500/hour effective Sept 13, 2022.","Carlos Campoy, SVP and CFO, to provide consulting at $500/hour effective Oct 1, 2022.","Both agreements have one-year terms with 30-day termination notice.","Peterson's services include clinical development; Campoy provides biotech and financial advice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352539,"accession_number":"0000950170-22-014751","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q2 2022 revenue $18M; cash $228M; restructuring extends runway to 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $228M at June 30, 2022, down from $305M at Dec 31, 2021.","Total revenue $18M for Q2 2022, up from $16M in Q2 2021; R&D expense $31M (+$5M YoY).","Company restructuring announced July 2022 aims to extend cash runway into 2025.","IND filings planned for CX-801 (IFN alpha-2b) and CX-2051 (EpCAM ADC) in H2 2023.","CX-2029 data update for squamous NSCLC expected Q4 2022; praluzatamab ravtansine also updating Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":35302000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352538,"accession_number":"0001193125-22-192874","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-07-13T23:59:59+00:00","items":["2.05","5.02"],"status":"ready","headline":"CytomX cuts ~40% of staff, $10M restructuring charge; COO, CFO, CMO to depart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~40% primarily in development and G&A; completion expected by Q4 2022.","Estimated restructuring charges of ~$10M, mainly severance, recorded in Q3 and Q4 2022.","Cash runway extended into 2025 as a result of the restructuring.","President/COO Amy Peterson to leave effective Sept 12, 2022; CFO Carlos Campoy and CMO Alison Hannah effective Sept 30, 2022.","Company to prioritize pre-clinical/early clinical pipeline with two INDs planned for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352537,"accession_number":"0001193125-22-188577","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-07-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CytomX Phase 2 breast cancer study: Arm A meets ORR endpoint but Arm B fails; program paused, partnership sought","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Arm A in HR+/HER2- breast cancer met primary endpoint: ORR 15% (central review) in 47 patients unselected for CD166 expression.","Arm B (TNBC) did not pass futility boundary (ORR <10%); enrollment in Arms B and C discontinued.","Safety: 30% discontinued for AE; Grade 3+ ocular 15%, neuropathic 10%. Lower toxicity at 6 mg/kg dose.","Company will not further advance program alone due to financial market conditions; seeking a partnership.","CytomX intends to present full Phase 2 data at a medical conference in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370100,"accession_number":"0001193125-22-177650","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CytomX shareholders elect McCarthy and Mohindru as directors, ratify E&Y, approve exec comp","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors Sean McCarthy and Mani Mohindru elected with ~68% of votes cast.","Ratification of Ernst & Young as auditor for FY2022 passed with 99.95% of votes cast.","Non-binding advisory vote on named executive officer compensation approved with ~93% support.","All proposals passed; broker non-votes recorded for directors and say-on-pay only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370099,"accession_number":"0000950170-22-007835","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX Q1 2022 revenue $17.1M; cash $263M; pipeline data expected H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $263M at March 31, 2022, down from $305M at Dec 31, 2021.","Total revenue $17.1M for Q1 2022, up from $16.0M in Q1 2021, primarily from AbbVie collaboration.","R&D expenses $30.6M (up $8.2M YoY); G&A $10.5M (up $1.3M YoY); operating loss implied.","Phase 2 praluzatamab ravtansine: Arm A enrollment complete; initial data for Arms A & B in H2 2022.","CX-2029 completed enrollment in squamous NSCLC cohort; data update expected in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":17136000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370098,"accession_number":"0001193125-22-105580","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX director John A. Scarlett to retire at June 15, 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John A. Scarlett, M.D. informed CytomX of his retirement from the board, effective at the next annual meeting on June 15, 2022.","Dr. Scarlett's retirement is not the result of any dispute or disagreement with the company.","The retirement is a planned departure at the end of his current term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389218,"accession_number":"0001193125-22-082793","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Frederick W. Gluck to retire from CytomX board effective June 30, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frederick W. Gluck to retire from CytomX board effective June 30, 2022.","Retirement not due to any dispute or disagreement with the company.","No replacement named; board will be reduced by one member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389217,"accession_number":"0000950170-22-002526","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CytomX reports Q4 rev $19.7M, cash $305.2M; CX-2029 18.8% ORR, CX-904 IND allowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $305.2M at Dec 31, 2021 vs $316.1M at Dec 31, 2020.","Q4 2021 revenue $19.7M (up from $16.4M in Q4 2020); FY 2021 revenue $69.6M (down from $100.4M).","CX-2029 Phase 2 in sqNSCLC: 18.8% objective response rate, 87.5% disease control rate; safety consistent.","CX-904 (EGFRxCD3 TCB) IND allowed; Phase 1 in advanced solid tumors to start H1 2022.","Praluzatamab ravtansine Phase 2 in breast cancer: initial data for Arms A & B expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":69573000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389216,"accession_number":"0001193125-22-041752","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-02-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX CFO Carlos Campoy takes temporary leave; VP Chris Ogden to act as interim principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Carlos Campoy begins temporary personal leave effective Feb 14, 2022, but remains CFO and principal financial officer.","Chris Ogden, VP Finance and Accounting, designated as interim principal accounting officer.","Ogden's annual base salary set at $315,270 with discretionary bonus target of 30% of salary.","Ogden has severance agreement providing up to 9 months base salary plus benefits and prorated bonus.","Ogden joined CytomX in Aug 2021 after 15 years at Eli Lilly, most recently as CFO of Lilly's diabetes division."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389215,"accession_number":"0001193125-22-029142","cik":1501989,"company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","form_type":"8-K","filed_at":"2022-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CytomX promotes Amy Peterson to President and COO; salary, equity grants disclosed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Peterson promoted to President and COO effective Feb 2, 2022; previously EVP & Chief Dev. Officer.","Annual base salary increased to $550,000; discretionary annual bonus target set at 50% of salary.","Received option for 200,000 shares at $4.13 strike price and 40,000 restricted stock units.","Dr. Sean McCarthy continues as Chairman and CEO; Peterson assumes President role formerly held by McCarthy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":831625167.2335957,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-07T23:59:59+00:00|389215"}